- Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints of Schirmer Test (p=0.0001) and ≥10 mm Schirmer Test Responder Proportions (p
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
Watch Aldeyra Therapeutics' latest callAldeyra Therapeutics (NASDAQ:ALDX) Q2 2025 Earnings Call · Replay · May 6, 2025Read the transcript of Aldeyra Therapeutics (NASDAQ:ALDX) Q2 2025 Earnings CallAldeyra Therapeutics, Inc. on 6ix
In the deck
Story so far
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
- Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
- Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
Earlier from Aldeyra Therapeutics
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
- Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
- Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference
- Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
- Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights
Later from Aldeyra Therapeutics
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap
- Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
- Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
- Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
- Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
Follow Aldeyra Therapeutics into a list and get an email when it puts out news.
Follow Aldeyra Therapeutics